{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:23:33Z","timestamp":1761186213772,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.mcna.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:23:04Z","timestamp":1749482584000},"page":"1331-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing Comorbidities in Heart Failure"],"prefix":"10.1016","volume":"109","author":[{"given":"Rachel","family":"Tobin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Rantanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Lyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Sennhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2025.04.011_bib1","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America","author":"Bozkurt","year":"2024","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjmed.2014.08.024","article-title":"Multimorbidity in heart failure: a community perspective","volume":"128","author":"Chamberlain","year":"2015","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.011_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.amjmed.2010.08.017","article-title":"Trends in comorbidity, disability, and polypharmacy in heart failure","volume":"124","author":"Wong","year":"2011","journal-title":"Am J Med"},{"issue":"18","key":"10.1016\/j.mcna.2025.04.011_bib4","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mcna.2025.04.011_bib5","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines-heart failure registry","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12955-020-01566-y","article-title":"Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review","volume":"18","author":"Comin-Colet","year":"2020","journal-title":"Health Qual Life Outcome"},{"issue":"20","key":"10.1016\/j.mcna.2025.04.011_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2025.04.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","article-title":"Blood pressure and heart failure","volume":"26","author":"Oh","year":"2020","journal-title":"Clin Hypertens"},{"issue":"4","key":"10.1016\/j.mcna.2025.04.011_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003613","article-title":"Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial","volume":"10","author":"Upadhya","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.mcna.2025.04.011_bib10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.011_bib12","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"Officers","year":"2002","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.011_bib13","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group","volume":"283","year":"2000","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.011_bib14","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","article-title":"Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.011_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10741-022-10238-6","article-title":"Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence","volume":"28","author":"Palazzuoli","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.011_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/cvr\/cvab120","article-title":"Concurrent diabetes and heart failure: interplay and novel therapeutic approaches","volume":"118","author":"Karwi","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"21","key":"10.1016\/j.mcna.2025.04.011_bib17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.011_bib18","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2025.04.011_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mcna.2025.04.011_bib20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2025.04.011_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ejhf.2693","article-title":"Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.011_bib22","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.mcna.2025.04.011_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1161\/CIRCULATIONAHA.116.026054","article-title":"Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction","volume":"135","author":"Verma","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2025.04.011_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2018.04.093","article-title":"Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: the PREFER in AF - HF substudy","volume":"265","author":"Siller-Matula","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCHEARTFAILURE.115.002285","article-title":"Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure registry","volume":"8","author":"Li","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurjhf\/hft093","article-title":"Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study","volume":"15","author":"Mulder","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11897-023-00642-w","article-title":"Antiarrhythmic treatment in heart failure","volume":"21","author":"Konemann","year":"2024","journal-title":"Curr Heart Fail Rep"},{"issue":"25","key":"10.1016\/j.mcna.2025.04.011_bib29","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2025.04.011_bib31","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical Practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib33","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1540-8167.2005.50062.x","article-title":"Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study)","volume":"16","author":"Doshi","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"9","key":"10.1016\/j.mcna.2025.04.011_bib34","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.mcna.2025.04.011_bib35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2025.04.011_bib36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.011_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.011_bib38","article-title":"PCI in patients with heart failure: current evidence, impact of complete revascularization, and contemporary techniques to improve outcomes","volume":"1","author":"Ahmad","year":"2022","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.011_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.011_bib40","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/heartjnl-2016-310794","article-title":"Heart failure in patients with kidney disease","volume":"103","author":"Tuegel","year":"2017","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.011_bib41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","article-title":"Management of heart failure in advancing CKD: core curriculum 2018","volume":"72","author":"House","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mcna.2025.04.011_bib42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mcna.2025.04.011_bib43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCRESAHA.122.321748","article-title":"The Cardio-kidney patient: epidemiology, clinical characteristics and therapy","volume":"132","author":"Schuett","year":"2023","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"10365","key":"10.1016\/j.mcna.2025.04.011_bib45","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.011_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0735-1097(02)01854-5","article-title":"Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure","volume":"39","author":"Horwich","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.mcna.2025.04.011_bib48","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.105.583666","article-title":"Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options","volume":"113","author":"Tang","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.000345","article-title":"Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"25","key":"10.1016\/j.mcna.2025.04.011_bib50","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"10266","key":"10.1016\/j.mcna.2025.04.011_bib51","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mcna.2025.04.011_bib53","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.mcna.2025.04.011_bib54","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.04.011_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","article-title":"The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials","volume":"218","author":"Kang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.011_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejheart.2006.08.003","article-title":"Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients","volume":"9","author":"Oldenburg","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.mcna.2025.04.011_bib57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jacc.2017.01.041","article-title":"Cardiovascular outcomes with minute ventilation-targeted adaptive servo-ventilation therapy in heart failure: the CAT-HF trial","volume":"69","author":"O'Connor","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.011_bib58","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/eurheartj\/ehu522","article-title":"Sleep disordered breathing and post-discharge mortality in patients with acute heart failure","volume":"36","author":"Khayat","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.mcna.2025.04.011_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cardfail.2012.05.003","article-title":"Central sleep apnea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure","volume":"18","author":"Khayat","year":"2012","journal-title":"J Card Fail"},{"issue":"19","key":"10.1016\/j.mcna.2025.04.011_bib60","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa051001","article-title":"Continuous positive airway pressure for central sleep apnea and heart failure","volume":"353","author":"Bradley","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2025.04.011_bib61","article-title":"Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure","volume":"12","author":"Yamamoto","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.mcna.2025.04.011_bib62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib63","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.011_bib64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","article-title":"Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the heart failure society of America Scientific Statements Committee","volume":"25","author":"Vest","year":"2019","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.011_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.mcna.2025.04.011_bib66","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.011_bib67","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"issue":"10456","key":"10.1016\/j.mcna.2025.04.011_bib68","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.011_bib69","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:02:50Z","timestamp":1761181370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0025712525000689"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.04.011","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing Comorbidities in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}